Abstract 474P
Background
We investigated KCNJ11 expression in different glioma tissue subtypes and its use as a predictor of glioma prognosis and sensitivity to temozolomide chemotherapy and determined the value of performance evaluation indicators.
Methods
Data on sex, age, histopathological type, WHO grade, IDH mutation, 1p/19q deletion, survival time, and KCNJ11 mRNA were collected from 516 patients with glioma. Expression levels and other data and uni- and multivariate Cox regression analyses were used to determine prognostic factors for patients with glioma. Data obtained from 603 cases with different glioma subtypes in TCGA database, 284 cases in REMBRANDT, and 264 cases in the United States database of the National Center for Biotechnology Information were verified to correlate KCNJ11 mRNA expression levels with the relationship between different clinical features and overall survival.
Results
KCNJ11 mRNA expression in 516 patients with different glioma subtypes correlated with histopathological type, WHO grade, IDH mutation status, 1p/19q co-deletion status, MGMT methylation, and WHO molecular classification (both P<0.05). Median survival times in the high KCNJ11 mRNA expression group were longer than those in the low expression group (P<0.05). Multivariate Cox regression analysis showed that age, tumor recurrence, WHO classification, IDH mutation, 1p/19q co-deletion, postoperative chemotherapy, and KCNJ11 mRNA expression were independent influencing factors of overall patient survival time. In the TCGA dataset, median overall survival times in the high expression group were longer than those in the low expression group (P<0.05). In the REMBRANDT dataset, median overall survival times in the high expression group was longer than those in the low expression group (P<0.05). In the GSE1101 dataset, median overall survival times in the high expression group was longer than those in the low expression group (P<0.05).
Conclusions
KCNJ11 mRNA expression was related to the degree of tumor malignancy and was an independent factor affecting overall survival time, and overall survival times of patients with high KCNJ11 mRNA expression are longer than those of patients with low KCNJ11 mRNA expression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
K. Zhou.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
586P - Clinical and molecular characteristics of colorectal adenosquamous carcinoma: A multicenter retrospective study
Presenter: Jun Huang
Session: Poster session 16
587P - Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): Results from the comprehensive genomic profiling (CGP) trial FPG500
Presenter: Francesco Schietroma
Session: Poster session 16
588P - Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study
Presenter: Valentino Martelli
Session: Poster session 16
589P - Simultaneous resection versus staged resection for conversion surgery for initially unresectable colorectal liver metastasis: A prospective cohort study
Presenter: Jianmin Xu
Session: Poster session 16
590P - A deep-learning model to predict the completeness of cytoreductive surgery in colorectal cancer with peritoneal metastasis
Presenter: QingFeng Lin
Session: Poster session 16
Resources:
Abstract
591P - Cost-utility of systemic anticancer therapy (SACT) with or without metastasectomy including local ablative therapy (LAT) for metastatic colorectal cancer (mCRC) patients
Presenter: Joel Kontiainen
Session: Poster session 16
592P - Survival analysis of surgical management options for goblet cell adenocarcinoma: Insights from machine learning clustering
Presenter: Marie Line El Asmar
Session: Poster session 16
593P - Treatment response and survival of patients with early onset colorectal cancer in the Netherlands
Presenter: Lauri Borghuis
Session: Poster session 16
594P - Genetic and transcriptomic analyses of Early-Onset Colon Cancer (EOCC): A post-hoc analysis of 2973 patients (pts) from two adjuvant randomized trials
Presenter: Annalice Gandini
Session: Poster session 16
595P - Adoption of remote patient monitoring in gastrointestinal oncology: A real-world experience from 1822 patients across 47 centers in France and Belgium
Presenter: Jerome Desrame
Session: Poster session 16